Clinical Trials Updated: PLN 74809 and Volixibat

The clinical trials resources page has been updated on 1/27/21 to reflect two clinical trials currently recruiting.

  1. PLN 74809: Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC). Pliant Therapeutics's PLN 74809 is an antifibrotic drug. It is in Phase 2a trial for PSC. The clinical trial is taking place in 22 centers throughout the U.S. The drug received Orphan Drug Designation for PSC. For more details on the trial, please see the clinicaltrials.gov listing and the Pliant Therapeutics site.

  2. Volixibat: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (VISTAS). The purpose of this clinical research study, sponsored by Mirum Pharmaceuticals, is to learn more about the use of the study medicine, volixibat, for the treatment of Glossary Link pruritus associated with Primary Sclerosing Cholangitis (PSC), and to assess the possible impact on the disease progression of PSC. For more details on the trial, please see the clinicaltrials.gov listing, the Mirum Pharmaceuticals site, and the businesswire article